Evidence map›Paper›PMID 38572335›Full record

ArticleArchivos peruanos de cardiologia y cirugia cardiovascular

[Cardiac Amyloidosis: Experience in a National Reference Cardiovascular Institute].

Juan Muñoz-Moreno, José Añorga-Ocmin, Sandra Espinola-García, Cristian Aguilar-Carranza, Walter Alarco-León

Abstract readEnglish Abstract
In one paragraph

Article in Archivos peruanos de cardiologia y cirugia cardiovascular. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. [Cardiac amyloidosis: a case report].Archivos peruanos de cardiologia y cirugia cardiovascular
    Article
  3. [Cardiac progression of systemic light chain amyloidosis].Archivos peruanos de cardiologia y cirugia cardiovascular
    Article
  4. [Molecular imaging in cardiac amyloidosis].Archivos peruanos de cardiologia y cirugia cardiovascular
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juan Muñoz-MorenoMédico residente de Cardiología. Instituto Nacional Cardiovascular - INCOR EsSalud. Lima, Perú. Instituto Nacional Cardiovascular - INCOR EsSalud Lima Perú.
José Añorga-OcminMédico residente de Cardiología. Instituto Nacional Cardiovascular - INCOR EsSalud. Lima, Perú. Instituto Nacional Cardiovascular - INCOR EsSalud Lima Perú.
Sandra Espinola-GarcíaMédico residente de Cardiología. Instituto Nacional Cardiovascular - INCOR EsSalud. Lima, Perú. Instituto Nacional Cardiovascular - INCOR EsSalud Lima Perú.
Cristian Aguilar-CarranzaMédico asistente del Laboratorio de Patología. Instituto Nacional Cardiovascular INCOR EsSalud. Lima, Perú. Instituto Nacional Cardiovascular INCOR EsSalud Lima Perú.
Walter Alarco-LeónUnidad de Insuficiencia Cardíaca, Trasplante Cardíaco e Hipertensión Pulmonar. Lima, Perú. Unidad de Insuficiencia Cardíaca, Trasplante Cardíaco e Hipertensión Pulmonar Lima Perú.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To determine the clinical, imaging and laboratory characteristics and one year after diagnosis survival of patients with cardiac amyloidosis in a national reference hospital. Materials and methods: Case series study. We evaluated the clinical characteristics, complementary examinations and survival of patients with cardiac amyloidosis diagnosed, treated and followed up in the Clinical Cardiology service of the National Cardiovascular Institute - INCOR EsSalud in Lima, Peru. Results: We found eight patients with diagnosis of cardiac amyloidosis. The median age was 64.5 years and 75% were male. The etiology of cases was unspecified cardiac amyloidosis (25%), transthyretin cardiac amyloidosis (37.5%), and light chain cardiac amyloidosis (37.5%). Symptomatic heart failure (NYHA II-III) was the most common initial presentation symptom (87.5%). The most frequent extracardiac manifestations were: sensory-motor neuropathy (62.5%), musculoskeletal (37.5%), nephropathy (25%), bilateral carpal tunnel syndrome (25%), monoclonal gammopathies (25%) and refractory pleural effusion (25 %). Survival at one year was 75% and the cause of the 2 deaths was sudden death. Conclusions: In this study of cardiac amyloidosis at a specialized center, the most frequent clinical manifestations were heart failure and sensory-motor neuropathy. Mortality was 25% per year, and in all cases as sudden death.

Indexed as

amyloidosisheart failurePeru

Identifiers

PMID38572335
PMCPMC10986346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.